Cartesian Therapeutics is a biotechnology company developing novel cellular immunotherapies to cure cancer. The companys lead product, Descartes-08, is a novel chimeric antigen receptor (CAR) _ based cell therapy to cure multiple myeloma.
Cartesian Therapeutics proprietary technology was developed by researchers at the National Institutes of Health (NIH).
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/cartesian-therapeutics” connections=”true” suffix=””]
Cartesians pipeline consists of multiple safety-profiled chimeric antigen receptor cell therapy products for treatment of multiple myeloma and other diseases.
Key investor in Cartesian Therapeutics includes, Schooner Capital a Boston-based private investment firm.
Recover your password.
A password will be e-mailed to you.